Abraxis receives tentative FDA approval for generic Kytril

SCHAUMBURG, Ill. Abraxis BioScience’s hospital business Abraxis Pharmaceutical Products has received tentative approval from the Food and Drug Administration for a generic version of the drug Kytril.

Granisetron hydrochloride, the generic of Kytril, is used for the prevention of nausea and vomiting in patients associated with cancer therapy and radiation.  The brand, which is made by Hoffmann-La Roche is set to lose its patent on Dec. 29 or on June 28, 2007, if the company receives pediatric exclusivity.

Barr Pharmaceuticals has also received a tentative approval for a generic of Kytril.